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BACKGROUND: Id-1 is overexpressed in and correlated with metastatic potential of prostate cancer. The role of Id-1 in this metastatic
process was further analysed.
METHODS: Conditioned media from prostate cancer cells, expressing various levels of Id-1, were used to stimulate pre-osteoclast
differentiation and osteoblast mineralisation. Downstream effectors of Id-1 were identified. Expressions of Id-1 and its downstream
effectors in prostate cancers were studied using immunohistochemistry in a prostate cancer patient cohort (N¼110).
RESULTS: We found that conditioned media from LNCaP prostate cancer cells overexpressing Id-1 had a higher ability to drive
osteoclast differentiation and a lower ability to stimulate osteoblast mineralisation than control, whereas conditioned media from PC3
prostate cancer cells with Id-1 knockdown were less able to stimulate osteoclast differentiation. Id-1 was found to negatively regulate
TNF-b and this correlation was confirmed in human prostate cancer specimens (P¼0.03). Furthermore, addition of recombinant
TNF-b to LNCaP Id-1 cell-derived media blocked the effect of Id-1 overexpression on osteoblast mineralisation.
CONCLUSION: In prostate cancer cells, the ability of Id-1 to modulate bone cell differentiation favouring metastatic bone disease is
partially mediated by TNF-b, and Id-1 could be a potential therapeutic target for prostate cancer to bone metastasis.
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Prostate cancer is the second leading cause of cancer-related death
in men in the United States (Jemal et al, 2008). Patients with
localised prostate cancer have a high 5-year survival rate (Klotz,
2005; Walz et al, 2007). However, once metastatic disease is
detected, the survival rate is greatly reduced (Sabbatini et al, 1999;
Loberg et al, 2005). Bone is the predominant site of distant
metastasis from prostate cancer (Coleman, 2006; Guise et al, 2006;
Vessella and Corey, 2006). Recent studies on inhibition of
osteolytic prostate cancer to bone metastasis have given promising
results on suppression of the ability and extent of metastases
establishment (Saad et al, 2002, 2004).
The importance of Id-1 in the metastatic progression of
various types of cancer has been shown (Sikder et al, 2003;
Wong et al, 2004; Ling et al, 2006). In prostate cancer, Id-1 has
been shown to promote cancer progression through various
mechanisms. Increased Id-1 expression was detected during
carcinogenesis of the prostate in the Noble rat (Ouyang et al,
2001). In human specimens, Id-1 expression in prostate cancer is
increased in comparison to benign prostatic hyperplasia specimens
(Ouyang et al, 2002a), and increased expression of Id-1 is
correlated with Gleason score, reflecting the aggressive nature of
Id-1-positive prostate cancers (Ouyang et al, 2002a; Coppe et al,
2004; Yuen et al, 2006). This information suggests that Id-1 is
important in both prostate cancer initiation and progression.
Delineation of the molecular mechanisms of Id-1 in prostate
carcinogenesis and cancer progression has recently begun. Id-1
promotes prostate cancer growth through inactivation of the
p16/pRB pathway (Ouyang et al, 2002b), and activation of the
epidermal growth factor receptor (Ling et al, 2004) and the MAPK
pathway (Ling et al, 2002). Id-1 promotes survival of prostate cancer
cells through the NF-kB pathway (Ling et al, 2003), and it regulates
the apoptotic response of cancer cells towards various chemo-
drugs (Zhang et al, 2007b), such that inactivation of Id-1 results in
increased sensitivity of prostate cancer cells to paclitaxel through
the JNK pathway (Zhang et al, 2006). Most importantly, Id-1 has
been shown to promote metastasis of prostate cancer. Id-1 promotes
angiogenesis through upregulation of VEGF (Ling et al, 2005),
while it also binds to caveolin-1 to induce epithelial–mesenchymal
transition in prostate cancer cells (Zhang et al, 2007a). In addition,
increased expression of Id-1 is significantly associated with shorter
survival of prostate cancer patients (Forootan et al, 2007). Taken
together, these results suggest that Id-1 has important roles in
prostate cancer carcinogenesis and metastatic progression.
Id-1 also functions to regulate the differentiation of osteoblasts.
Id-1 has been shown to regulate the expression of osteocalcin,
an osteoblast-differentiation marker (Tamura and Noda, 1994).
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by bone morphogenetic proteins (BMPs) (Peng et al, 2004). In an
in vivo breast cancer to bone metastasis model, the presence of
BMP-2 in a scaffold increased the metastatic frequency of the
breast cancer cell line SUM1315 (Moreau et al, 2007). On the other
hand, treatment with BMP-2 in the breast cancer cell line C2C12
resulted in increased expression of Id-1 (Katagiri et al, 1994; Nobta
et al, 2005; Raida et al, 2005; Langenfeld et al, 2006), while BMP-2
also positively regulated the expression of Id-1 in certain cell
contexts (Locklin et al, 2001; Takeda et al, 2004). Because BMPs
have very important roles in the development of bone metastasis
in prostate cancer cells (Feeley et al, 2005, 2006), it might be
possible that BMP-2 in the bone environment promotes meta-
stasis of cancer cells to bone through upregulation of the intrinsic
expression of Id-1 in cancer cells. BMP-2 increases the invasive-
ness of prostate cancer cells (Dai et al, 2005). Increased expres-
sion of BMP-7 has been detected in prostate cancer to bone
metastases, and high-level expression of BMP-7 is related to
osteoblastic activity of the metastatic lesion (Masuda et al,
2003). BMP-6 is highly expressed in prostate cancer to bone
metastases (Autzen et al, 1998), and a high level of BMP-6
in prostate cancer cells promotes osteoblastic activity of bone
cells (Dai et al, 2005). In a recent study, overexpression of
BMP-6 was shown to be correlated with increased Id-1 expres-
sion, suggesting that Id-1 might work downstream of BMP-6
in promoting prostate cancer progression (Darby et al, 2008).
Overall, these results imply that Id-1 has a role in prostate cancer
to bone metastasis.
Previously, we have shown that Id-1 expression in primary
prostate cancer is correlated with Gleason score (Ouyang et al,
2002a; Yuen et al, 2006), and in a separate cohort we also showed
that it is also correlated with mortality (Forootan et al, 2007). In
this study, we aimed to identify the role of Id-1 in prostate cancer
to bone metastasis and its possible downstream targets by studying
how bone cells respond to conditioned medium from prostate
cancer cells expressing various levels of Id-1.
MATERIALS AND METHODS
Cell culture conditions
Human prostate cancer cell lines LNCaP and PC3 (American Type
Culture Collection (ATCC)) were maintained in RPMI-1640
(Invitrogen, Carlsbad, CA, USA) supplemented with 5% FBS
(Invitrogen). An organ-confined prostate cancer cell line 22RV1
(from Professor Frankie Chan) and a human osteosarcoma cell line
SaOS-2 (ATCC) were maintained in RPMI-1640 supplemented with
10% FBS. A murine macrophage cell line RAW264.7 (ATCC) was
maintained in DMEM (Invitrogen) supplemented with 10% FBS.
LNCaP-pBabe-puro or pBabe-Id-1 stable transfectants were
generated previously (Ling et al, 2003), and were maintained in
RPMI-1640 supplemented with 5% FBS with intermittent selection
with puromycin (0.5mgml
–1). A PC3 stable transfectant containing
pLentiviral-shId-1 and the control PC3 pLentiviral-siCon were
generated as previously described using lentiviral-mediated
transduction (Cheung et al, 2006).
Plasmid
Id-1 expression plasmid, pcDNA-Id-1 was a gift from Dr Eiji Hara
(Kyoto Prefectural University of Medicine, Kyoto, Japan). pGL3-
IL6pro was generated by cloning of the IL-6 promoter region,
amplified using genomic DNA from PC3 cells and primers IL-6-
ProF1-Mlu1 (50-TATACGCGTCACTCCACCTGGAGACGCCT-30)
and IL-6-ProR1-Bgl2 (50-GCCAGATCTGAGTTCATAGCTGGG
CTCCT-30), into pGL3 (Promega, Madison, WI, USA). pGL3-
TNFbpro was generated by cloning of the TNF-b promoter region,
amplified using genomic DNA from PC3 cells and primers TNFb-
ProF1-Mlu1 (50-TATACGCGTGAAGCCTGTACTCAGCCAAGG-30)
and TNFb-ProR1-Bgl2 (50-GCTAGATCTCGGTAGTCCAAAGCAC
GAAG-30) into pGL-3. Amplification of these promoter regions was
performed by using the high-fidelity PCR System (Roche
Molecular Biochemicals, Indianapolis, IN, USA) and sequencing
was performed to confirm correct sequence of the insert.
pLentiviral vector containing a short hairpin interfering RNA
(shRNA) sequence against Id-1 mRNA (50-AACTCGGAATCC
GAAGTTGGA-30) (Zheng et al, 2004) was generated using the
BLOCK-iT lentiviral RNAi Expression System (Invitrogen). pLen-
tiviral vector control containing shRNA sequence (50-GCGTA
TTGCCTAGCATTAC-30), which has no significant homology to
any coding sequences in the human genome, was also generated.
Western blotting
Western blotting was performed as previously described (Kwok et al,
2005). Id-1 (C-20) antibody was from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA) and was used in a 1:1000 dilution. IL-6
antibody from Research & Diagnostics System Inc. (Minneapolis,
MN, USA) was used at a concentration of 5mgml
–1.T N F - b antibody
from Abcam Inc. (Cambridge, MA, USA) was used in a 1:1000
dilution. Actin antibody from Sigma-Aldrich (St Louis, MO, USA)
was used in a 1:3000 dilution.
Reverse-transcription–PCR
Reverse transcription–PCR was performed as previously described
(Ling et al, 2005). Primer sequences were as follows; IL-6F1
(50-CTGGATTCAATGAGGAGACTTGC-30) and IL-6R1 (50-GGACA
GGTTTCTGACCAGAAG-30); TNFb-F1 (50-CTCCCCATGACACCAC
CTGAACGTC-30) and TNFb-R1 (50-CTACAGAGCGAAGGCTCCA
AAGAAG-30); ActinF1 (50- GTGGGGCGCCCCAGGCACCA-30) and
Actin R1 (50-CTCCTTAATGTCACGCACGATTTC-30).
Luciferase reporter assay
Luciferase reporter assay was performed as previously described
(Ling et al, 2005).
Collection of conditioned medium
6.25 10
5 cells (LNCaP and PC3) were seeded in T-25 flasks. After
24h attachment and proliferation, the medium was replaced with
RPMI-1640 or DMEM containing 0.5% FBS, respectively. The
medium was collected after another 48h, filtered and stored at
 801C before use. In the rescue experiments, the conditioned
medium from LNCaP pBabe Id-1 cells was supplemented with
human recombinant TNF-b protein (Abcam) to 100pM,t h e
concentration previously shown to stimulate another human
osteosarcoma cell line MG-63 (Thomson et al, 1987). In the case of
PC3, the conditioned medium from PC-3 shId-1 cells was
supplemented with a TNF-b antibody (Abcam) to 2ngml
–1,t h e
concentration recommended by the manufacturer for neutralisation.
In vitro osteoclastogenesis assay
The conditioned medium from both cell types was mixed with
DMEM-10% FBS in a 1:1 ratio. Control was a mixture of 50%
RPMI-1640 and 50% DMEM-10% FBS. The conditioned medium
was then supplemented with 50ngml
–1 RANKL (R&D Systems).
5 10
3 RAW264.7 cells were seeded into each well of a 96-well
plate and were allowed to grow for 24h. Medium was then replaced
with the mixed conditioned medium after every 3 days. After an 8-
day treatment with the mixed conditioned medium, the number of
differentiated osteoclasts was determined using TRACP staining
assay kit according to the manufacturer’s instructions (Sigma).
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differentiated osteoclast-like cell. The total number of osteoclast-
like cells was counted in the entire well.
In vitro osteoblast mineralisation assay
The conditioned medium from both cell types was mixed with
RPMI-1640 10% FBS in a 1:1 ratio. RPMI-1640 was used instead of
conditioned medium as control. The mixed conditioned medium
was then supplemented with 10mM b-glycerophosphate and
50mgml
–1 ascorbic acid (both from Sigma). 5 10
3 SaOS-2 cells
were seeded into each well of a 24 well-plate. The culture medium
was changed every third day. On day 9, the medium was replaced
with the mixed conditioned medium and this medium was
changed every third day. On day 21, cells were stained for calcium
deposition by alizarin red S staining.
Alizarin red S staining
Cells were air-dried for 10min, fixed in 50% ethanol at room
temperature for 10min thrice. The cells were then stained with
10mgml
–1alizarin red S for 5min and were then washed with 1 
PBS. The staining extent was recorded by photography and the
retained dye was then extracted by extraction solution (20%
methanol and 10% acetic acid in water). The absorbance at 450nm
of the extracted solution was then measured.
Patients and specimens
A total of 110 archival formalin-fixed paraffin-embedded prostate
cancer specimens were obtained from the Department of
Pathology, The University of Hong Kong. These specimens were
incorporated into tissue microarray as previously described (Yuen
et al, 2006). Needle biopsy specimens used previously were not
included in this study because of insufficient tissue for immuno-
histochemical staining. Specimens were collected consecutively
excluding those from patients who had received previous
treatment directed against prostate cancer or those with insuffi-
cient tissue for tissue microarray incorporation. Details of patient
data are listed in Table 1.
Immunohistochemistry
Immunohistochemical staining was performed as previously
described using EnVisionþ system-HRP (Dako, Carpinteria, CA,
USA) (Yuen et al, 2007). A monoclonal antibody of IL-6 (R&D
Systems) was used at a concentration of 2.5mgml
–1 whereas
polyclonal antibody of TNF-b (Abcam) was used in a dilution of
1:500.
Quantification of immunohistochemical staining results
Evaluation was carried out as previously described (Yuen et al,
2007). In brief, the extent and intensity of the staining were graded
by an arbitrary scale ranging from 0 to 3 representing negative (0),
weak (1), moderate (2) and strong (3) staining. Negative and weak
staining was classified as low-level whereas moderate and strong
staining was classified as high-level expression. The number of
cases varies slightly because of the difference in interpretable cores
in tissue microarray.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 software (SPSS
Inc, Chicago, IL, USA). Differences in expression level between
groups/samples were analysed using chi-square, Fisher’s exact test
or Mann–Whitney-U tests where applicable. Spearman’s rank test
was applied to test correlations of the expression levels between
different proteins, and correlations of the expressions of different
proteins and Gleason grade. The association between the expres-
sion level and the risk of developing distant metastasis was
estimated using Kaplan–Meier analysis and compared using log-
rank test.
RESULTS
Overexpression of Id-1 in osteoblastic LNCaP cells
suppressed their ability to stimulate osteoblast
mineralisation and promoted their ability to stimulate
osteoclast differentiation
LNCaP cells (which express low levels of Id-1) were engineered to
ectopically express high levels of Id-1 by retroviral transduction.
Three clones (namely, clones 2, 3 and 6) with high levels of Id-1
expression were generated previously (Ling et al, 2002). These
clones also have higher MAPK pathway activity and PSA
expression than vector control clones (Ling et al, 2002, 2004).
Using western blot analysis, these three clones were confirmed as
expressing higher levels of Id-1 than vector control in culture
medium supplemented with 0.5% serum (Figure 1A). To analyse
whether overexpression of Id-1 modulates prostate cancer cell-
mediated bone cell differentiation, conditioned medium from
LNCaP pBabe vector control cells and Id-1 overexpressing cells
were collected and used for treating a human osteosarcoma cell
line, SaOS-2, which is capable of undergoing mineralisation, and
also a mouse macrophage-like cell line RAW264.7, which is
capable of differentiating into osteoclast-like cells upon appro-
priate stimulation. As shown in Figure 1B and C, SaOS-2 cells
underwent mineralisation after treatment with 10mM b-glycero-
phosphate and 50mgml
–1 ascorbic acid. Conditioned medium
from LNCaP pBabe vector control cells increased the extent of
mineralisation, as shown by alizarin red S assay. When quantita-
tively analysed, the degree of mineralisation of SaOS-2 cells treated
with conditioned medium from LNCaP pBabe vector control cells
(Figure 1C, open column) was significantly higher (Po0.05) than
the negative control (without prostate cancer conditioned medium,
black-filled column). These results suggest that conditioned
medium from LNCaP cells could stimulate the mineralisation of
human osteosarcoma SaOS-2 cells. However, when SaOS-2 cells
Table 1 Patient clinical and pathological features
Number of cases % Median (range)
Age 110 73 (56–94) years
Gleason score 110
GSo73 4 3 1
GSX77 6 6 9
Metastatic status 110
Non-metastatic 50 45
Metastatic 60 55
Gleason scoreo7 34
Non-metastatic 24 71
Metastatic 10 29
Gleason scoreX7 76
Non-metastatic 26 34
Metastatic 50 66
Core Gleason grade 314
GS¼28 2
GS¼3 160 51
GS¼4 100 32
GS¼54 6 1 5
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expressing high levels of Id-1, mineralisation was severely
inhibited (Figure 1B and C). The extent of mineralisation detected
by retained alizarin red S dye was significantly lower in SaOS-2
cells treated with conditioned medium from LNCaP cells over-
expressing Id-1 (grey columns, Po0.05 for each of the three
clones, compared with either vector control conditioned medium
or control medium). These results suggest that ectopic expression
of Id-1 inhibits LNCaP-induced osteoblast mineralisation.
As shown in Figure 1D and E, treatment of RAW264.7 cells with
control medium resulted in only 3.3±1.5 differentiated osteoclast-
like cells per well (Figure 1E, black-filled column). The number of
differentiated osteoclast-like cells was similar (1.7±0.6, P40.05)
when RAW264.7 cells were treated with conditioned medium from
LNCaP pBabe vector control cells, suggesting that conditioned
medium from LNCaP cells is incapable of stimulating osteoclast
differentiation. However, when RAW264.7 cells were treated with
conditioned medium from LNCaP pBabe Id-1 cells, the number of
differentiated osteoclast-like cells was significantly higher (clone 2:
8.3±2.5, clone 3: 10.7±2.9 and clone 6: 12±2, grey columns,
Po0.05 for each the three clones compared with either vector
control conditioned medium or control medium). These results
suggest that ectopic expression of Id-1 in LNCaP cells increases
their ability to stimulate osteoclast differentiation. Taken together,
these results provide evidence that Id-1 expression in LNCaP
results in reduced ability to stimulate osteoblast activity and
increased ability to stimulate osteoclast activity.
Downregulation of Id-1 in the osteolytic prostate cancer
cell line PC3 reduces its ability to stimulate osteoclast
differentiation
We analysed whether the knockdown of Id-1 in prostate cancer
cells would also affect their ability to mediate bone cell activities.
Using lentiviral infection with shRNA, we established a stable
clone of the osteolytic PC3 prostate cancer cell line (which
endogenously expresses high levels of Id-1) that expressed low
levels of Id-1. As shown in Figure 2A, the Id-1 protein level was
significantly reduced in PC3 pLenti-shId-1 when compared with
control PC3 pLenti-shCon cells. SaOS-2 cells mineralised when
cultured in osteogenic medium containing both b-glyceropho-
sphate and ascorbic acid, as shown using alizarin red S assay
(Figure 1B and C). When the conditioned media from these two
cell lines were applied to SaOS-2 cells, we found that mineralisa-
tion of SaOS-2 cells was inhibited regardless of the expression level
of Id-1 (Figure 2B). These results suggest that reduction of Id-1
expression does not affect PC3-inhibited osteoblast mineralisation.
On the other hand, reduced Id-1 expression in PC3 cells led to
significant reduction of its ability to induce osteoclast differentia-
tion (Po0.05). As shown in Figure 2C and D, treatment of
RAW264.7 with conditioned medium from PC3 pLenti shCon cells
resulted in 26.3±8.3 osteoclast-like cells per well, whereas only
1.3±1.2 osteoclast-like cells were observed when RAW264.7 cells
were treated with control medium (open column vs black-filled
column). In addition, when RAW264.7 cells were treated with
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Figure 1 The effects of Id-1 overexpression in LNCaP prostate cancer cells in prostate cancer cell-mediated bone cell activities. Three independent
clones of Id-1 overexpressing cells previously generated were used in this study. (A) Western blot analysis shows increased Id-1 protein expression
compared with vector control. (B) Alizarin red S assay; conditioned medium from LNCaP-Id-1 clones inhibited mineralisation of SaOS-2 osteosarcoma cells,
whereas conditioned medium from LNCaP-vector control cells stimulated mineralisation of SaOS-2 osteosarcoma cells when compared with control.
(C) Quantitative analysis of the extent of mineralisation. (D) Conditioned medium from LNCaP-Id-1 clones stimulated the differentiation of RAW264.7 cells
to osteoclast-like cells, whereas medium from LNCaP-vector control conferred no significant effect when compared with control. Representative area under
 200 magnification. (E) Quantitative analysis of the osteoclast differentiation assay. Columns represent the mean values from three independent
experiments±s.d.
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osteoclast-like cells were observed per well (grey-filled column).
These results suggest that conditioned medium from PC3 cells
induces macrophage to osteoclast differentiation, and that silen-
cing Id-1 in osteolytic PC3 prostate cancer cells inhibits the ability
of their conditioned medium to induce osteoclast differentiation.
Id-1 negatively regulates the expression of TNF-b
To analyse whether downstream factors of Id-1 are responsible for
its pro-osteolytic effect in prostate cancer cells, we used RT–PCR
to test the expression of several secretory factors in prostate cancer
cells expressing various levels of Id-1. We found that TNF-b
mRNA expression was reduced in LNCaP overexpressing Id-1
compared with LNCaP vector control cells, whereas it was
increased in PC3 cells expressing low levels of Id-1 compared
with PC3 vector control cells (Figure 3A). We went on to study
whether Id-1 could modulate the promoter activity of TNF-b.
Using PCR, we amplified an B500-bp upstream region of TNF-b
and cloned it into pGL-3 (Promega) for promoter luciferase
reporter assay. We found that the expression level of Id-1 was
negatively correlated with TNF-b promoter activity in LNCaP cells,
such that increased Id-1 by overexpression reduced the promoter
activity, whereas reduced Id-1 by siRNA knockdown enhanced the
promoter activity (Figure 3B). These results suggest that Id-1
negatively regulates TNF-b promoter activity. To analyse whether
the protein level of TNF-b was affected by Id-1, we also performed
western blotting for protein extracted from LNCaP and PC3 cells
expressing various levels of Id-1. As shown in Figure 3C,
overexpression of Id-1 in LNCaP cells resulted in reduced protein
expression of TNF-b whereas knockdown of Id-1 in PC3 cells
resulted in increased TNF-b protein expression. Overall, these
results suggest that Id-1 might negatively regulate TNF-b at the
transcriptional level.
Id-1 was negatively correlated with TNF-b in human
prostate cancer specimens
To test whether the regulatory relationship between Id-1 and TNF-
b can be observed in clinical materials, we studied whether
expression level of Id-1 is correlated with TNF-b expression in
human prostate cancer specimens using immunohistochemistry in
a prostate tissue microarray described previously (Yuen et al,
2006). As shown in Figure 4, high-level expression of Id-1 was
significantly associated with a low-level expression of TNF-b in the
prostate cancer specimens (Fisher’s exact test, P¼0.03). However,
expression of TNF-b did not significantly correlate with Gleason
score (chi-square, P¼0.321) or development of distant metastases
(Kaplan–Meier, P¼0.310). These results suggest that Id-1 might
regulate TNF-b in primary prostate cancer, although a larger
sample size would be needed to determine the relationship
between Id-1, TNF-b and metastasis. Id-1 has previously been
shown to correlate with Gleason score. In this study, we also
correlated Id-1 and TNF-b with the Gleason score of the tumours
and Gleason grade of individual cores. We found that although
Id-1 was again significantly correlated with Gleason grade of
individual cores in our cohort (Table 2a, r¼0.356, Po0.001),
TNF-b did not correlated with either Gleason score of the tumours
(r¼ 0.028, P¼0.709) or Gleason grade of the individual cores
(Table 2b, r¼ 0.04, P¼0.532).
Id-1 modulates prostate cancer-mediated bone cell activity
partially through TNF-b
Tumour necrosis factor-b has been shown to be expressed in
osteoblast-like cells (Bilbe et al, 1996). It has also been shown to
have a role in stimulating osteoblast proliferation (Frost et al,
1997) and osteoblast-mediated osteoclast differentiation (Thomson
et al, 1987). In this study, we found that prostate cancer cells
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Figure 2 The effects of Id-1 knockdown on PC3-mediated bone cell activities. (A) PC3 shId-1 cells were generated by lentiviral transduction and the
reduction in Id-1 expression was confirmed using western blot analysis. (B) Conditioned media from both PC3 shCon and shId-1 cells conferred inhibitory
effects on SaOS-2 mineralisation, indicating that knockdown of Id-1 is not sufficient to modulate the ability of PC3 cells to stimulate osteoblast mineralisation.
(C) Conditioned medium from PC3 shId-1 cells had a lower ability to stimulate osteoclast differentiation when compared with that from PC3 shCon cells.
(D) Quantitative analysis of osteoclast differentiation in PC3. Columns represent the mean values from three independent experiments±s.d.
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sexpressing different levels of Id-1 have both modulated levels of
TNF-b and an ability to stimulate osteoblast mineralisation and
osteoclast differentiation. Therefore, we hypothesised that Id-1
regulates the expression of TNF-b that leads to differential ability
to stimulate bone cell activities. To test this hypothesis,
recombinant TNF-b protein was added to LNCaP-Id-1-derived
conditioned medium whereas TNF-b antibodies were added to
PC3-shId-1-derived conditioned medium. As shown in Figure 5,
addition of TNF-b recombinant protein to LNCaP-Id-1-derived
conditioned medium resulted in an increased ability of the
medium to stimulate osteoblast mineralisation. This result
suggests that suppression of TNF-b in LNCaP-Id-1 cells might be
responsible for the reduced ability of the conditioned medium to
induce osteoblast mineralisation. However, neither addition of
TNF-b recombinant protein into LNCaP-Id-1-derived conditioned
medium, nor addition of TNF-b antibodies into PC3-shId-1-
derived conditioned medium had any significant effect on the
ability of the medium to stimulate osteoclast differentiation (data
not shown). These results suggest that modulation of the activity of
TNF-b in PC3 conditioned medium is not sufficient to alter the
ability of the medium to induce osteoclast differentiation. Taken
together, these results suggest that overexpression of Id-1 in
LNCaP cells results in reduced ability of the cells to induce
osteoblast mineralisation through Id-1-mediated reduction of
TNF-b expression. However, TNF-b alone is not sufficient to
explain all of the prostate cancer cell-mediated bone cell
differentiation resulting from modulating Id-1 expression level.
Owing to the fact that TNF-b could not completely rescue the Id-
1-mediated phenotypes, other factors must also participate. In a
preliminary study, we found that IL-6 expression is modulated in
cells expressing various levels of Id-1 (Figure 6A). A correlation
between the expression of the two factors was revealed when
benign prostatic hyperplasia specimens were also included in the
analysis (Figure 6B, r¼0.226, P¼0.013). To analyse whether Id-1
regulates IL-6 at a transcriptional level, we cloned the promoter of
IL-6 into a pGL-3 luciferase reporter plasmid and co-transfected
this plasmid with siId-1. However, the promoter activity, within
1000bp upstream of the transcriptional start site, was not
significantly affected upon Id-1 knockdown in the transient
transfection (Figure 6C). We speculate that Id-1 might regulate
IL-6 expression in an indirect manner rather than affecting its
immediate transcription, an area that requires further analysis. As
IL-6 is correlated with both Gleason grade of the individual cores
(Table 2c) and distant metastasis in our patient cohort, regardless
of the Gleason score of the tumours (Figure 6D and E), IL-6 might
be one factor that could explain the partial rescue of the Id-1-
induced phenotypes by recombinant TNF-b.
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Figure 3 Id-1 negatively regulates TNF-b expression. (A) Using RT–PCR, we found that the expression of TNF-b mRNA was lower in Id-1
overexpressing LNCaP cells and was higher in Id-1 knockdown PC3 cells compared with respective controls. Water was used in place of template in
the negative control. (B) Id-1 negatively regulated the promoter activity of TNF-b, suggesting that the regulation might be at the transcriptional level.
(C) Western blot showed similar results at the protein level. Columns represent the mean values from three independent experiments±s.d.
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Figure 4 Representative tissue cores of immunohistochemical staining.
Id-1 is significantly negatively correlated with TNF-b expression in human
prostate cancer specimens. A cross-tabulation of Id-1 and TNF-b
expression in the patient cohort is shown below the immunohistochemistry
images.
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sDISCUSSION
In this study, we have shown that conditioned medium from
LNCaP cells overexpressing Id-1 had a higher ability to stimulate
osteoclast differentiation than control, whereas Id-1 knockdown in
PC3 cells resulted in reduced ability of the conditioned medium to
induce osteoclast differentiation. These results suggest that Id-1
has a role in prostate cancer-mediated osteoclast differentiation. In
addition, Id-1 also modulates prostate cancer-mediated osteoblast
mineralisation. Medium derived from LNCaP-Id-1 cells had a
lower ability to stimulate osteoblast mineralisation when com-
pared with their vector control counterpart. However, the medium
derived from PC3-shId-1 is still incapable of inducing osteoblast
mineralisation, suggesting that Id-1 might be sufficient to inhibit
prostate cancer cell-mediated osteoblast mineralisation, but is not
the sole regulator of this event. A possible reason for this might be
the presence of other Id proteins within the family in PC3. In fact,
Id-2 has also been shown to be upregulated in prostate cancer
(Coppe et al, 2004; Yuen et al, 2006), whereas Id proteins have
been shown to co-express and have redundant roles in some
cellular contexts (Lyden et al, 1999).
In search of downstream targets of Id-1 involved in the observed
phenotypes, we tested the expression levels of several secretory factors
that are known to modulate osteoblast/osteoclast activities using
semiquantitative RT–PCR. We found that TNF-b might be a
downstream target of Id-1. Knowing that Id-1 binds to other helix-
loop-helix transcription factors to inhibit their ability to bind DNA
and regulate transcription, we proceeded to study, using luciferase
reporter assay, whether modulating Id-1 expression could affect the
promoter activity of TNF-b. We found that overexpression or
knockdown of Id-1 in LNCaP cells resulted in reduced and enhanced
TNF-b promoter activity, respectively. We also analysed the expression
levels of TNF-b using immunohistochemistry in 110 human prostate
cancer specimens for which Id-1 expression status was already known
(Yuen et al,2 0 0 6 ) .W ef o u n dt h a t ,i no u rp r o s t a t ec a n c e rp a t i e n t
cohort, high-level expression of Id-1 was associated with low TNF-b
expression, which is consistent with our in vitro findings.
Tumour necrosis factor-b has been shown to affect the activities
of osteoblasts and osteoclasts (Thomson et al, 1987; Frost et al,
1997). After confirming the link between Id-1 and TNF-b, we went
on to study whether TNF-b contributes to the Id-1-mediated
phenotype. We found that TNF-b was responsible for Id-1-
mediated inhibition of prostate cancer cell-mediated osteoblast
mineralisation, but was not accountable for Id-1-mediated activa-
tion of prostate cancer cell-mediated osteoclast differentiation.
Table 2 (a) Correlation of Id-1 expression levels and Gleason grade of individual cores; (b) correlation of TNF-b expression levels and Gleason grade of
individual cores; and (c) correlation of IL-6 expression levels and Gleason grade of individual cores
GS¼2G S ¼3G S ¼4G S ¼5
Gleason grade Number (%) Number (%) Number (%) Number (%)
(a)
Id-1 expression score
Negative 0 (0) 25 (20) 3 (4) 1 (3)
Weak 5 (63) 53 (43) 27 (32) 10 (27)
Moderate 2 (25) 33 (27) 32 (38) 9 (24)
Strong 1 (13) 12 (10) 23 (27) 17 (46)
(b)
TNF-b expression score
Negative 1 (17) 26 (22) 16 (19) 8 (20)
Weak 2 (33) 36 (30) 22 (26) 19 (49)
Moderate 2 (33) 36 (30) 28 (33) 9 (23)
Strong 1 (17) 22 (18) 19 (22) 3 (8)
(c)
IL-6 expression score
Negative 4 (67) 66 (54) 18 (27) 10 (27)
Weak 2 (33) 33 (27) 24 (36) 7 (19)
Moderate 0 (0) 19 (15) 20 (30) 15 (41)
Strong 0 (0) 5 (4) 5 (8) 5 (14)
(a) Spearman’s rank test: r¼0.356, Po0.001. (b) Spearman’s rank test: r¼ 0.40, P¼0.532. (c) Spearman’s rank test: r¼0.317, Po0.001.
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Figure 5 Recombinant TNF-b protein rescued the effect of Id-1
overexpression in prostate cancer-mediated osteoblast mineralisation.
(A) Alizarin red S assay shows that TNF-b partially reversed the inhibitory
effect of overexpressing Id-1 in LNCaP-mediated osteoblast mineralisation.
(B) Quantitative analysis of the extent of mineralisation in alizarin red S
assay. Light and dark grey columns in bar chart represent results from
conditioned medium with and without the addition of TNF-b recombinant
protein, respectively. Columns represent the mean values from three
independent experiments±s.d.
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sThese results suggest that TNF-b has only a partial role in Id-1-
modulated prostate cancer cell-mediated bone cell activities.
As TNF-b only partially rescued the phenotypes induced by
modulating Id-1 in prostate cancer cells, we speculated that
secretory factors other than TNF-b might also be involved. In a
preliminary study, we identified IL-6 as a possible mediating
factor, but the mechanisms of Id-1-mediated induction of
osteoclast differentiation and inhibition of osteoblast mineralisa-
tion are far from clear. To fully understand Id-1-mediated
phenotypes, a DNA microarray analysis should be performed that
could identify more Id-1 downstream targets. Alternatively, the
identification of secretory proteins from the media from cells
expressing various levels of Id-1 could also be performed by
concentrating the media, analysing the concentrated media in a 2D
gel system and identifying the differentially expressed proteins
using mass spectrometry. We believe that combinatorial effects
from all the Id-1 downstream factors could help to explain the
mechanisms of Id-1-mediated prostate cancer-mediated osteoclast
differentiation and osteoblast mineralisation.
Recent clinical studies have revealed that bisphosphonate, which
functions to block bone destruction, reduces, delays and relieves
prostate cancer to bone metastasis (Saad et al, 2002, 2004; Saad,
2005). These results suggest that osteoclast-driven bone resorption
is an important target for treatment of prostate cancer to bone
metastasis. Most prostate cancer to bone metastases are osteo-
blastic in nature (Koeneman et al, 1999). The reason for effective
treatment targeting bone resorption may be mainly because of the
osteolytic initial stage during the establishment of the bone
metastasis. Recent studies on Wnt signalling have shown
important evidence that prostate cancer to bone metastasis might
transit from an early osteolytic stage to late osteoblastic stage
(Hall et al, 2005, 2006, 2008). We found that overexpression of
Id-1 in LNCaP cells reduced their ability to stimulate osteoblast
mineralisation and enhanced their ability to promote osteoclast
differentiation, whereas Id-1 knockdown in PC3 cells reduced
their ability to stimulate osteoclast differentiation. These results
suggest that Id-1 might have an important role in promoting
prostate cancer-mediated osteoclast differentiation, and that it
could be a target to inhibit prostate cancer to bone metastasis.
In addition, the cell–cell interactions in prostate metastasis in
the bone environment are extremely complex. Prostate cancer
cells, osteoblasts and osteoclasts interact with each other in the
micro-environment and therefore, prostate cancer cells might
stimulate osteoblasts to stimulate osteoclasts and vice versa. This
study did not focus on how these three-dimensional interactions
could be modulated by Id-1. A transwell system containing
osteoclasts in the top layer and osteoblasts in the bottom layer with
conditioned medium from prostate cancer cells might help to
elucidate the interaction between these three cell types.
In conclusion, Id-1 has already been shown to promote
proliferation, invasion and survival of prostate cancer cells. This
study has identified a new role of Id-1 in prostate cancer to bone
metastasis and piloted other studies to analyse whether Id-1 could
be used as a prognostic marker and therapeutic target in prostate
cancer to bone metastasis.
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Figure 6 Factors other than TNF-b might also be involved in Id-1-modulated prostate cancer-mediated bone cell differentiation. IL-6 mRNA expression is
positively correlated with Id-1 expression in LNCaP and PC3 (A), and Id-1 is also positively correlated with IL-6 expression in primary prostate specimens
(B). (C) Promoter assay shows that IL-6 promoter activity was not modulated by reduced expression of Id-1. Columns represent the mean values from
three independent experiments±s.d. (D) Patients with high level of IL-6 staining in their primary prostate cancer had a higher risk of developing distant
metastases. (E) A similar result was obtained when only patients with high Gleason score (X7) were analysed.
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